Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. And the pivotal, ...

AbbVie's experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out ...

“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 ...

Growing older is the greatest risk factor for acquiring Parkinson’s disease and many people live with symptoms for several years before being diagnosed. Often people in early stages of Parkinson’s ...

"Using these findings, we could identify individuals with specific deficiencies and administer oral riboflavin and biotin ...

The company plans to submit a new drug application for tavapadon to the US Food and Drug Administration next year.

Why digital measurements startup Koneksa Health thinks it can help pharma measure if their drugs are effective in people with ...

The new Ochsner site will contribute to uncovering additional genes as well as examine health disparities and care access for ...

A study from the University of Arizona shows that the protein PNA5 helps protect brain cells, offering a promising avenue for ...

Two teams of scientists have recently come up with potential breakthroughs with preventing a serious side effect of Parkinson ...

Intra-Cellular Therapies is developing Lenrispodun for the treatment of patients with Parkinson's Disease in a phase 2 study.

Researchers at the Foundation have uncovered new insights into the complex link between dopamine and rest tremor in Parkinson ...